If you’re considering Mounjaro, or already using it, understanding the price matters. This guide explains how Mounjaro pricing works in the UK, what changed in recent years, and the options available to you through Numan.
Mounjaro prices increased on October 1st 2025
Other treatments available through Numan may have different pricing structures
Check if weight loss treatment is right for you
The private UK price of Mounjaro was updated in 2025 as part of a global pricing alignment by the manufacturer. Since then:
Prices have been updated to reflect the change
Other weight loss medications such as Wegovy remain unaffected
NHS pricing continues to operate separately from private prescriptions
Clinical care, monitoring, and support through Numan remain unchanged
If you're a Numan member, your current price is always shown clearly before you confirm any order. Mounjaro will only be prescribed after a clinician has carefully reviewed your case and confirmed that it’s clinically appropriate for you.
The prices below include clinician reviews, prescription, and medication delivery.
| Dose (mg) | Price (GBP) |
|---|---|
| 2.5 | 229 |
| 5 | 239 |
| 7.5 | 289 |
| 10 | 309 |
| 12.5 | 329 |
| 15 | 339 |
Higher doses contain more tirzepatide, which directly affects cost. Pricing reflects the medication itself alongside UK clinician prescribing, safety monitoring, and ongoing support.
If you’d like to talk through your options, our clinical team is here to help - reach out anytime to discuss your plan, as your care and support remain our priority.
When Mounjaro launched in the UK, the initial UK price was set lower than in many other countries. This helped increase access during early supply pressure.
In 2025, the manufacturer moved to align UK pricing more closely with global levels.
Importantly:
This was a manufacturer-led global pricing decision
It wasn't driven by Numan, nor was it caused by UK-specific supply issues
As with most branded medications supplied internationally, pricing is ultimately set at manufacturer level rather than by individual clinics.
Your clinical care and health coaching: We’ll keep your plan safe, evidence‑based, and tailored to you.
Other treatments (including Wegovy) pricing: If you’re eligible, it remains an alternative clinically-proven medication.
NHS costs: Patients receiving tirzepatide (Mounjaro) via the NHS aren't affected by any private price changes.
If you’re currently using Mounjaro, you have multiple options. Depending on your clinical profile and goals, you may be able to:
Continue on your current dose
Adjust your dose if clinically appropriate
Switch to Wegovy if suitable
Pause medication and focus on lifestyle support
Any change is always reviewed by a clinician to ensure it's safe and appropriate for you.
For some patients, Wegovy may be a suitable alternative. In many cases, switching can occur at the time your next weekly dose would be due. Your clinician will confirm the safest and most appropriate timing for you.
If you’re considering a change, our clinical team will guide you through:
Whether switching is appropriate
The right starting dose
How to transition safely
What outcomes may be expected based on clinical evidence and your individual profile
We understand that price plays a role in long-term treatment decisions. If you’re reviewing your plan, speak to us first.
Your clinician can help you:
Review whether your current dose is still appropriate
Explore alternative treatments
Optimise your wider weight loss plan
Ensure you stay safe and supported
We strongly advise avoiding unlicensed sellers. Unregulated medications are unsafe and may cause you harm.
Medication pricing is set by the manufacturer and influenced by global market conditions, not individual clinics. As Mounjaro is a branded medication supplied internationally, future price adjustments, be it up or down, would depend on broader manufacturer decisions rather than changes at Numan.
What we can commit to is transparency and competitiveness. If pricing ever changes again, we’ll communicate clearly and in advance. We continually review the treatments we offer to ensure they remain fairly priced within the UK private healthcare market.
And importantly, you’re never limited to one option. If pricing shifts, alternatives such as Wegovy or other clinically-appropriate treatments remain available, with our clinicians ready to help you choose the safest and most suitable plan for your goals and budget.
Price changes are frustrating, but we promise to keep your care transparent and supportive. Whether you continue with Mounjaro, adjust your dose, or change your treatment, we’ll help you choose a safe, effective plan that works for you.
1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., … STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., … Vilsbøll, T. (2021). Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice, 75(2). doi:10.1111/ijcp.13731
Updated:
